FDA: Risk of Methanol Toxicity With Certain Hand Sanitizers
Hand sanitizers containing methanol, or wood alcohol, present a danger to individuals as the substance can be toxic when absorbed through the skin or life-threatening if ingested.
Hand sanitizers containing methanol, or wood alcohol, present a danger to individuals as the substance can be toxic when absorbed through the skin or life-threatening if ingested.
The Drug Enforcement Administration (DEA) is proposing a reduction in the amount of Schedule II controlled substances that can be manufactured in the US next year.
Findings from the phase 3 ASCLEPIOS I and II studies showed that treatment with ofatumumab (Novartis) resulted in a highly significant and clinically meaningful reduction in the number of confirmed relapses, compared with teriflunomide, a pyrimidine synthesis inhibitor, in patients with relapsing forms of multiple sclerosis.
The Food and Drug Administration (FDA) has approved Myobloc (rimabotulinumtoxinB injection; US WorldMeds) for the treatment of chronic sialorrhea in adults.
The Food and Drug Administration (FDA) has granted Fast Track designation to ecopipam (Emalex Biosciences), an investigational agent for the treatment of Tourette syndrome (TS).
A phase 3 trial evaluating an investigational therapy for the treatment of pantothenate kinase-associated neurodegeneration did not meet its primary or secondary end points.
The FDA has rejected the supplemental New Drug Application for Hetlioz (tasimelteon; Vanda Pharmaceuticals) for the treatment of jet lag disorder.
Only 29% of 2016 survey respondents reported that they strongly agreed that the burden of herpes zoster in patients aged 50 to 59 years old is sufficient to make a vaccine important.
According to the Food and Drug Administration (FDA), AveXis Inc, the manufacturer of the gene therapy Zolgensma, was aware of an issue related to “data manipulation” prior to approval, but did not inform the Agency until after the product was approved.
Galcanezumab was found to be beneficial in patients with treatment-resistant migraine, according to results from the phase 3 CONQUER study.